Society rejects CMSS COI code

The American Rhinologic Society (ARS) adopted a COI policy that permits transparent interactions between industry and ARS and its leadership.
In so doing, ARS declined to adopt the Council of Medical Specialty Society's Code for Interaction with Companies, which it said does not permit company funding and relationships. “ARS leaders believe such an extreme policy would be harmful to patients,“ noted a statement. The new policy does not set dollar amounts or limit interactions. It requires transparency—ARS said it will list relationships on its website—and creates ground rules for these relationships to prevent influence.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.